Efficacy of 17β-Estradiol on Depression: Is Estrogen Deficiency Really Necessary?
J Clin Psychiatry 2002;63(5):451 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Ahokas and colleagues1 recently published the results of an open-label study in which 23 women who suffered from severe postpartum depression (mean ± SD Montgomery-Asberg Depression Rating Scale [MADRS] total score = 40.7 ± 2.8; range, 35–45) received micronized 17β-estradiol (E2) sublingually for 8 weeks. The results were impressive: 39% of subjects experienced full remission of depression (MADRS total score ≤ 7) after 1 week of treatment, and almost 83% experienced full remission after 2 weeks. Two patients sustained antidepressant benefit at 4 weeks following treatment discontinuation. At baseline, 16 of 23 subjects were hypogonadal (serum E2 level < 110 pmol/L), and all subjects had a serum E2 level < 200 pmol/L.